<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

3 min read

Spotlight on Medtronic Neuromodulation: NANS 2023

By Anne Staylor on 2/10/23 11:40 AM

Medtronic executives Nnamdi Njoku and Charlie Covert discuss Medtronic’s latest initiatives in Neuromodulation in an interview with SmartTRAK at NANS 2023

Nnamdi Njoku, Medtronic’s Senior Vice President and President Neuromodulation, and Charlie Covert, Vice President and General Manager of Pain Therapies, discuss what’s new for Medtronic Neuromodulation, expected market growth in 2023 and strategies for driving growth in spinal cord stimulation (SCS) and deep brain stimulation (DBS) in an interview with SmartTRAK at the North American Neuromodulation Society (NANS) 26th Annual Meeting held January 12-15, 2023 in Las Vegas, Nevada.

To find out more about the Company’s latest innovations, expanding indications and what’s next for Medtronic Neuromodulation, click on the following video recorded live at NANS 2023. (27:57 minutes.) Specific interview topics by time code are outlined below. A link to download a complete transcript of the interview is also provided below.

Continue Reading
2 min read

Neuromodulation Trends: SmartTRAK at NANS 2023

By Thomas Wallick on 1/10/23 9:00 AM

SmartTRAK takes a look back at Neuromodulation Trends in 2022 and looks forward to reporting on emerging trends at NANS 2023

Anne Staylor, SmartTRAK's Executive Editor VP & GM, Neuro Therapies, will again be attending and reporting on the North American Neuromodulation Society Annual Meeting (NANS), this year being held in Las Vegas, January 12-15th. If you would like to meet with Anne while at NANS, just click here.

Last year, Anne published a prescient article from the NANS 25th Annual Meeting titled "Neuromodulation Trends in 2022 and Beyond" in which she identified key trends from the meeting in Orlando and provided an outlook of what’s on the horizon for neuromodulation. This included trends in research and technology that will help shape the markets for spinal cord stimulation (SCS), deep brain stimulation (DBS) and peripheral nerve stimulation (PNS), advances in closed-loop therapies, improving care through digital solutions and driving growth through expanding indications.

To download and read the complete "Neuromodulation Trends in 2022 and Beyond" article, just click here.  

Continue Reading
2 min read

Wrestling with Issues and Headwinds: Q322 Neuromodulation Market Recap

By Anne Staylor on 12/29/22 9:30 AM

Growth in the SCS and DBS segments remained soft in Q322 as companies continue to wrestle with macro-environmental issues and currency headwinds

Neuromodulation continued to face a challenging macro environment in Q322 related to stubborn inflationary pressures, currency exchange headwinds and unpredictable surges in COVID affecting supply chains and healthcare staffing in certain geographies. However, some competitors reported seeing steady signs of improvement in the quarter and are looking to expanded indications and new technologies to help drive growth.

Among the many topics covered in detail in our comprehensive Q322 Neuromodulation Market Recap* are:

Continue Reading
  • There are no suggestions because the search field is empty.

Follow Us on Social Media

Recent Articles